FDA Calendar

Company Name Bristol-Myers Squibb Co.
Drug Name Opdivo (sBLA)
Event Name FDA decision on Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications
Event Date 03/05/2018
Outcome Date 03/06/2018
Outcome FDA approved 480 mg dosing for Opdivo on Mar 6, 2018
Drug Status
Rival Drugs
Market Potential
Other Approvals The current approved dosing of OPDIVO is 240 mg administered as an intravenous infusion over 30 minutes every 2 weeks
Return to FDA Calendar